NCT05054166View on ClinicalTrials.gov

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

CompletedOBSERVATIONAL
Enrollment

14

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

August 1, 2021

Study Completion Date

August 30, 2021

Conditions
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Interventions
OTHER

No intervention, it was a retrospective study.

This study aimed to retrospectively investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.There was no intervention.

Trial Locations (1)

Unknown

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER